MNM Bioscience

MNM Bioscience specializes in advanced cancer diagnostics, leveraging AI technology to interpret genetic mutations for personalized treatment plans. The company serves patients, biopharma companies, and investors by providing predictive and prognostic models that are ready for licensing. Operating in the healthcare and biotechnology market, MNM Bioscience's business model focuses on collaborative partnerships and licensing agreements. Revenue is generated through these partnerships and the licensing of their proprietary AI frameworks and diagnostic algorithms. The company's technology translates various mutation types into actionable biological insights, aiding in the prediction of drug responses and identification of new drug targets.

Keywords: cancer diagnostics, AI technology, genetic mutations, personalized treatment, predictive models, prognostic models, licensing, biopharma partnerships, drug response prediction, biotechnology.